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Abstract
For a two-group comparative study, a stratified inference procedure is
routinely used to estimate an overall group contrast to increase the preci-
sion of the simple two-sample estimator. Unfortunately most commonly
used methods including the Cochran-Mantel-Haenszel statistic for a binary
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outcome and the stratified Cox procedure for the event time endpoint do
not serve this purpose well. In fact, these procedures may be worse than
their two-sample counterparts even when the observed treatment allocations
are imbalanced across strata. Various procedures beyond the conventional
stratified methods have been proposed to increase the precision of estima-
tion when the naive estimator is consistent. In this paper, we are interested
in the case when the treatment allocation proportions vary markedly across
strata. We study the stochastic properties of the two-sample naive estima-
tor conditional on the ancillary statistics: the observed treatment allocation
proportions and/or the stratum sizes, and present a biased-adjusted estima-
tor. This adjusted estimator is asymptotically equivalent to the augmenta-
tion estimators proposed under the unconditional setting (Zhang and others,
2008). Moreover, this consistent estimation procedure is also equivalent to
a rather simple procedure, which estimates the mean response of each treat-
ment group first via a stratum-size weighted average and then constructs the
group contrast estimate. This simple procedure is flexible and readily appli-
cable to any target patient population by choosing appropriate weights for
each treatment effect estimate. All the proposals are illustrated with the data
from a cardiovascular clinical trial, whose treatment allocations are imbal-
anced. Ancillary statistic; Augmentation estimation procedure; Conditional
inference; CMH statistic; Mixture population
1 Introduction
In a comparative, randomized study, suppose that we are interested in estimating
an overall group difference, θ, between a treatment and a control via their indi-
vidual population parameters, τ2 and τ1, respectively. For example, τ is the mean
3
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value of the study subject’s outcome variable and θ = τ2 − τ1. Assume that the
study utilizes a M : 1 random treatment allocation rule for assigning patients to
the treatment and control groups. Although the primary analysis of the study is
generally based on a two-sample empirical counterpart θˆ of θ, a stratified infer-
ence procedure is often utilized to increase the estimation precision for θˆ (Val-
liant, 1993; Miratrix and others, 2013). Moreover, when the observed allocation
proportions of patients assigned to either arm vary substantially across strata, a
stratified estimator θˆS , has been generally perceived as less biased than θˆ.
Unfortunately a number of routinely used stratified procedures cannot be guar-
anteed to increase the precision nor reduce the bias for estimating θ, especially
when θ is non-linearly related to τ1 and τ2. As an example, consider a simple case
where the outcome is a binary variable and θ is the odds ratio (OR) of the event
rates τ′s. That is,
θ =
τ2/(1 − τ2)
τ1/(1 − τ1) .
The two-sample empirical counterpart is
θˆ =
τˆ2/(1 − τˆ2)
τˆ1/(1 − τˆ1) ,
where τˆ j is the observed empirical counterpart of τ j, j = 1, 2. For a large ran-
domized study, θˆ is consistent for θ. Now, suppose that one considers a stratified
inference procedure with K strata to estimate θ. Let the observed stratum sizes be
n1, n2, · · · , nK and n = ∑Kk=1 nk. For the jth group in the kth stratum, let the group
size be n jk, the true event rate be τ jk, pˆik = n2k/nk and wˆk = nk/n, j = 1, 2; k =
1, · · · ,K. A commonly used stratified estimate for θ is based on the Cochran-
Mantel-Haenszel (CMH) statistics (Mantel and Haenszel, 1959), which results in
θˆS =
∑K
k=1 τˆ2k(1 − τˆ1k)pˆik(1 − pˆik)wˆk∑K
k=1(1 − τˆ2k)τˆ1kpˆik(1 − pˆik)wˆk
,
4
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where τˆ jk is the observed empirical counterpart of τ jk. Note that even when nk →
∞ and pˆik → M/(M + 1), k = 1, · · · ,K, θˆS converges to
θS =
∑K
k=1 τ2k(1 − τ1k)wk∑K
k=1(1 − τ2k)τ1kwk
,
where wk, the limit of wˆk, is the mixing proportion of the kth stratum in the study
population. In general, θS , θ, and therefore, θˆS is an inconsistent estimator.
Moreover, θS is not a simple weighted average of the stratum-specific OR’s as
usually interpreted by the practitioners. Here, the kth weight is proportional to
(1 − τ2k)τ1kwk, a rather complex form of the underlying stratum-specific event
rates.
In survival analysis, a stratified inference procedure, which is routinely used
for comparing two groups, is to estimate the hazard ratio (HR) θ under a two-
sample proportional hazards model (Cox, 1972). Here, the outcome variable is
the time to a specific event. The corresponding stratified method is the stratified
Cox procedure (Cox, 1972; Mehrotra and others, 2012), which suffers from the
same limitation of the CMH method for the binary outcome. More details will be
given in Section 4 of this paper.
Alternatives to aforementioned conventional stratified procedures have been
studied extensively when the simple estimator θˆ is consistent. For this case, the
goal is mainly to increase the estimation precision of θˆ with the baseline covariate
information (Koch and others, 1998; Zhang and others, 2008; Moore and van der
Laan, 2009; Rosenblum and van der Laan, 2010; Tian and others, 2012). The per-
formance of such alternative estimation procedures are assessed under an “uncon-
ditional” setting by considering all possible realizations of the estimator generated
under the random treatment allocation rule utilized in the study. Now, suppose that
(i) pˆi′ks, the observed proportions of study patients assigned to the treatment group,
5
Hosted by The Berkeley Electronic Press
vary substantially across strata, and/or (ii) wˆ′ks, the observed proportions of the
patients in each stratum, are substantially different from the underlying w′ks. Then
generally, for the case with a practical sample size, the observed naive estimate
θˆ would not be close to θ. It is not clear, however, how to empirically quantify
the bias of θˆ. One possible approach to handle this problem would be based on
a conditional inference principle via ancillary statistics for the treatment differ-
ence θ (Kalbfleisch, 1975). For the present case, both the empirical proportions
of patients assigned to the treatment {pˆik, k = 1, · · · ,K} and the empirical pro-
portions of the strata {wˆk, k = 1, · · · ,K} are ancillary statistics. The distribution
of (θˆ − θ) conditional on such ancillary statistics would be more “relevant” and
informative than its unconditional counterpart to study the stochastic behavior of
θˆ (Senn, 1989; Pocock and others, 2002). Specifically, we consider all realiza-
tions of θˆ generated from the random allocation rule utilized in the study, but
{(pˆik, wˆk), k = 1, · · · ,K} of each realized sample would be the same as its observed
counterparts. By doing so, the individual realizations in the above conditional
sample space are obtained under the experimental condition similar to the ob-
served one. In this paper, using this procedure, one can empirically quantify the
bias of θˆ and then obtain a consistent estimator for θ by modifying θˆ. It is in-
teresting to note that the above modified estimator is identical or asymptotically
equivalent to the augmentation estimators proposed by Zhang and others (2008);
Tsiatis and others (2008) and Tian and others (2012) under the unconditional set-
ting. Moreover, the above modified estimator is also equivalent to a rather simple
estimator obtained via a mixture estimation procedure across strata. Specifically,
for the above example for θ being the OR, we first estimate the overall event rate
for the control arm using a weighted average of stratum-specific event rate es-
6
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timates, where the weight for the kth stratum-specific estimate is wk, the target
proportion of patients from the kth stratum. Similarly, we estimate the overall
event rate for the treated arm. Then, we construct the OR estimate with these two
overall event rate estimates. The details are given in Sections 2 and 3. In Section
4, we apply the proposal to the case with the censored event time observations.
All the procedures are illustrated with the data from a comparative, randomized
cardiovascular clinical trial.
2 Modifying the naive estimator θˆ in the presence of
treatment allocation imbalance
Using the notations in the Introduction for the general case, that is, let τ j and τˆ j be
the population mean and its empirical counterpart of the subject’s outcome vari-
able for the jth group, respectively, and let τ jk and τˆ jk be the corresponding quan-
tities in the kth stratum, k = 1, · · · ,K; j = 1, 2. Let θ = g(τ1, τ2) and θˆ = g(τˆ1, τˆ2),
where g(·, ·) is a given smooth function. With a random assignment allocation rule
and the random sampling assumption of subjects in each group and stratum, for
large nk, k = 1, · · · ,K, it is straightforward to show that the joint distribution of
(θˆ−θ) and (wˆ1−w1, · · · , wˆK−wK , pˆi1−p¯i, · · · , pˆiK−p¯i)′ is approximately normal with
mean 0 and covariance matrix Σˆ given in the Appendix A, where p¯i =
∑K
k=1 wˆkpˆik.
Heuristically, it follows that the conditional distribution of
(θˆ − θ)∣∣∣{(wˆk − wk, pˆik − p¯i), k = 1, · · · ,K}
7
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is approximately normal with a mean of
bˆpiw =g˙1(τ
†
1, τ
†
2)
K∑
k=1
τˆ1k
(
wˆk(1 − pˆik)
1 − p¯i − wk
)
+ g˙2(τ
†
1, τ
†
2)
K∑
k=1
τˆ2k
(
wˆkpˆik
p¯i
− wk
)
and a variance of
σˆ2piw =
K∑
k=1
{
g˙2(τ
†
1, τ
†
2)
2wˆ2kσˆ
2
2k + g˙1(τ
†
1, τ
†
2)
2wˆ2kσˆ
2
1k
}
,
where
τ†j =
K∑
k=1
wkτˆ jk, j = 1, 2,
g˙ j(τ1, τ2) is the partial derivative of g(τ1, τ2) with respect to τ j and σˆ2jk is a con-
sistent estimator for the variance of τˆ jk, j = 1, 2. Note that the above large sample
normal approximation is not straightforward. The theoretical justification of this
approximation to the conditional distribution is given in Appendix A. The above
conditional distribution shows that θˆ is in general inconsistent for θ when there are
treatment allocation imbalances within individual strata or wˆ′ks are different from
w′ks. An obvious consistent estimator for θ by directly adjusting θˆ is
θˆpiw = θˆ − bˆpiw.
Note that θˆpiw is a sum of θˆ and a linear combination of (wˆk −wk) and (pˆik − p¯i), k =
1, · · · ,K and is asymptotically equivalent to the augmentation estimators pro-
posed and discussed in Zhang and others (2008); Moore and van der Laan (2009)
and Tian and others (2012). Note also that the augmentation procedures in the
literature do not have wˆk − wk, k = 1, · · · ,K, as one of the augmented terms. On
the other hand, from the semi-parametric efficiency argument, it is a trivial exten-
sion to do so, when wk, k = 1, · · · ,K are known. As a result, unconditionally, θˆpiw
minimizes the asymptotical variance of the sum of θˆ and any linear combination
8
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of {(wˆk −wk), (pˆik − p¯i), k = 1, · · · ,K}. However, all the augmented estimators were
developed to improve efficiency over the naive estimator θˆ under an unconditional
setting for which the naive estimator θˆ is consistent.
When wk for the study population is unknown, one may consider an adjusted
estimator θˆpi based on the conditional distribution of θˆ − θ given {pˆik − p¯i, k =
1, · · · ,K} only. Specifically, θˆpi = θˆ − bˆpi, where
bˆpi =g˙1(τ
†
1pi, τ
†
2pi)
K∑
k=1
wˆkτˆ1k
(
1 − pˆik
1 − p¯i − 1
)
+ g˙2(τ
†
1pi, τ
†
2pi)
K∑
k=1
wˆkτˆ2k
(
pˆik
p¯i
− 1
)
.
The variance of θˆpi can be estimated consistently by
σˆ2pi = σˆ
2
piw + n
−1
K∑
k=1
wˆk
{
g˙2(τ
†
1pi, τ
†
2pi)(τˆ2k − τˆ2) + g˙1(τ†1pi, τ†2pi)(τˆ1k − τˆ1)
}2
,
where
τ†jpi =
K∑
k=1
wˆkτˆ jk.
It is interesting to note σˆ2pi is greater than σˆ
2
piw due to the the sampling variation
from {wˆk, k = 1, · · · ,K}. This adjusted estimator would not be unbiased under the
conditional setting with the additional conditioning event, {(wˆk − wk), k = 1, · · · ,K} .
It is important to note that there is no general rule on the choice of ancillary statis-
tics. This topic has been discussed extensively in the literature. In practice, the
choice of the ancillary statistics would be made on a case by case basis. For our
present case, the choice ancillary statistics, {pˆik} and {wˆk} was similar to those of
the inference for analyzing multiple 2× 2 tables (Fraser, 2004). The choice of the
ancillary statistic {pˆik} only was also suggested by Senn (1989) and Pocock and
others (2002).
As an example, consider the data from a cardiovascular trial “Valsartan in
acute myocardial infarction (VALIANT) study” (Pfeffer and others, 2003) to il-
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lustrate the above estimation procedures. There were three arms in this study, the
patients in the first group were treated by ARB valsartan, the second group was
with ACE inhibitor captopril and the third one was a combination of these two
drugs. For illustration, we consider the time to the first hospitalization or death as
the endpoint and compare the monotherapy (combing two treatment groups) with
the combo therapy. The study enrolled a total of 14,703 patients were equally as-
signed to three arms. The median follow-up time was 24.7 months after random-
ization. For the entire study, there is no difference with respect to the endpoint
considered here. In Fig. 1, we show the Kaplan-Meier curves for this endpoint
for two comparators. On the other hand, with the data from 302 patients in Aus-
tralia, the monotherapy somehow appears to be statistically significantly better
than its combo counterpart (see Fig. 2). Note that Australia was the only country
among 24 countries participated in the VALIANT study, whose patients tend to
have better outcomes for the monotherapy than those for the combo therapy.
We will discuss the case with an event time as the endpoint in Section 4. Here,
let us consider the outcome from the above study to be a binary, either the patient
had event by or at month 18. Note that there were no censored observations in the
study before month 18. There are two important patient’s covariates, which are
related to this binary endpoint: BMI and history of diabetes. For simplicity, we
dichotomize BMI with a cutoff value of 25 and create four strata (i.e, 1: low BMI
and no diabetic history; 2: low BMI and with diabetic history; 3: high BMI and
no diabetic history; 4: high BMI and with diabetic history). Table 1 shows the
number of 302 Australian patients assigned to each treatment group with respect
to the four strata, whose sizes (wˆ1, wˆ2, wˆ3, wˆ4) = (0.24, 0.06, 0.54, 0.16). Note that
if the randomization scheme worked well, the treatment allocation ratio (mono
10
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vs. combo) would be around 2:1. From Table 1, there is a non-trivial treatment
allocation imbalance with respect to these two factors.
The naive estimate θˆ for the OR of two event rates (combo vs. mono) at month
18 is 1.99 with a 0.95 confidence interval of (1.12, 3.51) in favor of monother-
apy. The corresponding CMH estimate is 1.83 with a 0.95 confidence interval of
(1.03, 3.25). Using the empirical strata weights {wˆi}, the bias adjusted estimate
θˆpi is 1.73 with a 0.95 confidence interval of (0.96, 3.12). The confidence interval
includes one, suggesting that the group difference is not statistically significant
based on the bias adjusted estimator. If we assume that the true mixing propor-
tions for the Australia substudy are identical to the observed proportions in the
entire VALIANT study, i.e., (w1,w2,w3,w4) = (0.24, 0.04, 0.53, 0.19), then θˆpiw
for OR becomes 1.75 with a slightly different 0.95 confidence interval of (0.97,
3.13), also indicating an insignificant treatment effect.
3 A simple consistent stratified estimator for θ with
two group-specific weighted averages of the stra-
tum mean outcomes
Under a stratification setting with K strata, the mean of the outcome τ j can be
rewritten as
∑K
k=1 wkτ jk, and can be estimated consistently with τ
†
j =
∑K
k=1 wkτˆ jk, j =
1, 2. It follows that
θˆnew = g(τ
†
1, τ
†
2)
is a consistent estimator unconditionally or conditionally on {pˆik, k = 1, · · · ,K}
and/or {wˆk, k = 1, · · · ,K}. It is interesting to note that this new estimator is asymp-
11
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totically equivalent to the bias-adjusted estimator θˆpiw. This equivalence is due to
the fact that
τ†1 − τˆ1 = −
K∑
k=1
τˆ1k
(
wˆk(1 − pˆik)
1 − p¯i − wk
)
,
τ†2 − τˆ2 = −
K∑
k=1
τˆ2k
(
wˆkpˆik
p¯i
− wk
)
,
and
g(τˆ1, τˆ2) − g(τ†1, τ†2) ≈ g˙1(τ†1, τ†2)(τˆ1 − τ†1) + g˙2(τ†1, τ†2)(τˆ2 − τ†2) = bˆpiw.
Note also that when {wk, k = 1, · · · ,K} is not known, θˆnew can be replaced by
θˆnewpi = g(τ
†
1pi, τ
†
2pi),
with τ†jpi =
∑K
k=1 wˆkτˆ jk, j = 1, 2. For this case, the resulting θˆnewpi is asymptotically
equivalent to θˆpi discussed in Section 2.
Considering the estimator θˆnewpi with wˆk as the weights, first τ
†
jpi estimates the
mean response of the subjects in arm j by a weighted average with the observed
proportion of the stratum size as the weight. One then constructs a group con-
trast measure with these two resulting treatment group-specific estimators. Note
that this estimation procedure for the between-group difference is constructed in a
rather different way from the conventional stratified counterparts. For the conven-
tional stratification methods, we first estimate the stratum specific group contrasts
and then empirically combine them across strata, whose weights may not have
clinical or physical interpretation. Moreover, the conventional stratified methods
for the case with a non-linear g(τ1, τ2) may not increase the estimation efficiency
and introduce nontrivial bias as discussed in the previous section. Since θˆnew or
θˆnewpi is asymptotically equivalent to its augmentation estimation procedure, this
estimator is always more efficient than θˆ asymptotically.
12
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As an estimator for the marginal mean response, τ†j not only serves as the
building block for adjusting the bias of the naive estimator but also provides im-
portant reference level in interpreting the group contrast measure θ. For example,
although both (τ†1, τ
†
2) = (0.050, 0.095) and (0.500, 0.667) yield the same OR of
2.0, they may have quite different implications in practice. The conventional strat-
ified estimator and the estimators θˆpiw and its corresponding equivalent augmented
counterparts do not have the benchmark value from the control arm for clinical
decision makings.
In the VALIANT example, the estimated event rate is τ†1pi = 0.67 with a 0.95
confidence interval of (0.61, 0.74) for monotherapy and τ†2pi = 0.77 with a 0.95
confidence interval interval of (0.72, 0.83) for combo therapy based on the ob-
served stratum sizes. Note that if we are interested in a difference group contrast
measure, for instance, the event rate difference as θ, these values are readily avail-
able from this simple new procedure to make inferences.
4 APPLICATION TO THE CASE WITH THE EVENT
TIME OUTCOME VARIABLE
The most commonly used stratification estimation procedure is based on the strat-
ified Cox model (Mehrotra and others, 2012). Here, the parameter of interest is
the overall HR θ by assuming that the two hazard functions are proportional of
each other over the entire study time. As discussed extensively in the statistical
and medical literature, the HR estimate is difficult to interpret especially when
the PH assumption is violated (Uno and others, 2014, 2015). The stratified Cox
procedure follows the same approach as other conventional stratified methods for
13
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analyzing non-censored outcomes. That is, for each stratum, we assume that the
PH assumption is plausible. We then obtain the HR estimate for each stratum,
and combine those estimates. The resulting estimator is asymptotically equiv-
alent to linearly combining the log-transformed stratum-specific HR estimators
over K strata. The weight of the combination is proportional to the inverse of the
variance estimate for the log-transformed stratum-specific HR estimate. However,
even when PH assumption holds within each stratum, the PH assumption for entire
study population is almost always violated (see Appendix B). Consequently, the
combined HR estimator from the stratified Cox procedure cannot be interpreted
as the HR for the entire population. Now, the question is whether we can apply
the marginal treatment effect method discussed in Section 3 to deal with the HR.
Unfortunately, since the hazard function is not a probability measure, the over-
all hazard function cannot be expressed as a weighted average of stratum-specific
hazard functions. The simple estimation approach discussed in Section 3 cannot
be applied to the case using HR as the group contrast.
There are several alternative summary measures to quantify survivorship for
each treatment group. For example, one may consider the median survival time.
However, it is in general not a weighted average of stratum-specific median failure
times either. Two other alternatives are the event rate and restricted survival time
at a specific time point (Uno and others, 2014, 2015).
For the t−year event rate τ j, j = 1, 2, we can use the same approach discussed
in Section 3. That is, we estimate τ j by
τ†j =
K∑
k=1
wkτˆ jk or τ
†
jpi =
K∑
k=1
wˆkτˆ jk,
where τˆ jk = Sˆ jk(t) and Sˆ jk(·) is the Kaplan-Meier estimator for the survival func-
14
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tion of the group j in the kth stratum. Then θˆnew = g(τ
†
1, τ
†
2) and θˆnewpi = g(τ
†
1pi, τ
†
2pi)
are unbiased for estimating θ even when there are markedly observed treatment
allocation imbalance.
As an example, we also consider the substudy analysis for Australia in VALIANT
study. The estimated event rate (death or hospitalization) at t = 1000 days is 0.88
in the combo therapy group and 0.77 in the monotherapy group. The naive es-
timate of the OR of two event rates is 2.33 with a 95% confidence interval of
[1.39, 3.93], suggesting that the event rate by t = 1000 days for patients receiv-
ing monotherapy is significantly lower than that for combo therapy. Recall that
there are four strata defined by BMI and diabetic history with the stratum size,
(wˆ1, wˆ2, wˆ3, wˆ4) = (0.24, 0.06, 0.54, 0.16). With the above simple procedure, the
adjusted event rate is 0.87 in the combo therapy group and 0.77 in the monother-
apy group. The resulting estimator θˆnew of the OR is 1.92 (95% confidence inter-
val: 0.88 to 4.22). This new OR estimator is smaller than the unadjusted counter-
part with a p-value of 0.103.
The second alternative is the t−year mean survival time (t-MST) up to time
point t. That is, E{min(T, t)} for survival time T, which is the area under the sur-
vival function up to the time point t (Uno and others, 2014, 2015). The corre-
sponding parameter summarizing the treatment effect is g(τ1, τ2), a contrast be-
tween t-MSTs from two groups, where τ j is the t-MST in group j. For instance,
g(τ1, τ2) is the ratio of two t-MSTs. For the above VALIANT study, the area un-
der the Kaplan-Meier curves for the monotherapy and combo therapy arms are
τˆ1 = 395 days and τˆ2 = 260 days up to t = 1000 days, respectively. That means in
the future, if we treat the patient with the new treatment up to 1000 days, we ex-
pect on average, the patient receiving monotherapy will have 395 event-free days,
15
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and 260 event-free days for patients receiving combo therapy. If we let θ be the
ratio of two t-MSTs at 1000 days, θˆ = 1.58 with a 95% confidence interval of
(1.15, 2.18) and a p-value less than 0.01.
Now, for a stratified analysis with respect to the t-MST measure, we first esti-
mate this parameter with a weighted sum of stratum-specific t-MSTs, that is,
τ†j =
K∑
k=1
wkτˆ jk or τ
†
jpi =
K∑
k=1
wˆkτˆ jk,
where τˆ jk =
∫ t
0
Sˆ jk(u)du. For the above numerical example, τ
†
1pi = 394 days and
τ†2pi = 280 days based on observed {wˆk, k = 1, 2, 3, 4}. The ratio of these two,
θˆnew = 1.41 with a 95% confidence interval of (1.03, 1.92). Although statistically
the monotherapy is significantly better than the combo, the confidence interval of
the ratio of two t-MSTs is shifted toward the null value of one.
5 REMARKS
The marginal treatment effect approach discussed in Section 3 is rather flexible,
which can handle the case when the target patient population is different from the
study population. For example, in a cardiovascular clinical study, the majority of
study patients is male. The target future population may be evenly divided with
respect to gender. With the conventional stratified analysis, it is difficult to figure
out the overall treatment difference for the target population.
The choice of the stratification factors is important. If we overly stratify the
study, that is, some factors are not related or mildly related to the outcome, the pre-
cision of the stratified inference procedure can be worse than the naive two-sample
estimate. Recently Tian and others (2012) and Bloniarz and others (2015) gener-
16
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alized the augmentation method originally proposed by Zhang and others (2008)
to efficiently select relevant baseline covariates among a set of pre-specified can-
didates under an unconditional setting for adjusting the consistent two-sample
estimator. It is not clear how to apply this idea to handle the case when there is
a potential imbalance with respect to a large set of stratification factors to avoid
over-stratification. Further research on appropriate selection of stratification fac-
tors is warranted.
APPENDIX
Appendix A: Asymptotical Properties of the Naive Estimator
Conditional on Observed Allocation Imbalances.
Firstly, we assume that the observed data consist of n i.i.d observations (Yi,Ri, Xi), i =
1, · · · , n, where Yi is the response, Ri = 1 or 2 is the treatment indicator for group
1 and 2, respectively, and Xi takes values 1, 2, · · · ,K, representing the stratum of
the ith subject. Without loss of generality, let θˆ = g(τˆ1, τˆ2), where τˆ j is the ob-
served mean response in arm j and τˆ jk is the observed mean response in arm j of
stratum k, j = 1, 2; k = 1, · · · ,K. Our goal is to derive the limiting distribution of
n1/2(θˆ − θ)
conditional on
wˆk − wk, pˆik − p¯i, k = 1, · · · ,K,
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where n =
∑K
k=1 nk. To this end, we first have the expansion
θˆ − θ
wˆ1 − w1
...
wˆK − wK
pˆi1 − p¯i
...
pˆiK − p¯i

= n−1
n∑
i=1

g˙2(τ1,τ2)I(Ri=2)(Yi−τ2)
pi
+
g˙1(τ1,τ2)I(Ri=1)(Yi−τ1)
1−pi
I(Xi = 1) − w1
...
I(Xi = K) − wK
{I(Xi=1)−w1}{I(Ri=2)−pi}
w1
...
{I(Xi=K)−wK }{I(Ri=2)−pi}
wK

+

ξθ
0
ξpi
 ,
where pi = pr(Ri = 2) and |ξθ| + |ξpi| = o(n−1/2) almost surely. Let
Un = n−1/2
n∑
i=1
Ui and Vn = n−1/2
n∑
i=1
Vi,
where
Ui =
g˙2(τ1, τ2)I(Ri = 2)(Yi − τ2)
pi
+
g˙1(τ1, τ2)I(Ri = 1)(Yi − τ1)
1 − pi
and
Vi =

I(Xi = 1) − w1
...
I(Xi = K) − wK
{I(Xi=1)−w1}{I(Ri=2)−pi}
w1
...
{I(Xi=K)−wK }{I(Ri=2)−pi}
wK

By central limit theorem, (Un,V ′n)
′ converges weakly to (U0,V ′0)
′, a multivariate
normal with mean 0 and a variance-covariance matrix
Σ =

σ2θ D
′
θw D
′
θpi
Dθw Σww 0
Dθpi 0 Σpipi
 ,
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where
σ2θ =
g˙2(τ1, τ2)σ2Y2
pi
+
g˙1(τ1, τ2)σ2Y1
1 − pi
σ2Y j = var(Yi|Ri = j), Dθw = (dw1, · · · , dwK)′, Dθpi = (dpi1, · · · , dpiK)′,
dwk = g˙2(τ1, τ2)wk(τ2k − τ2) + g˙1(τ1, τ2)wk(τ1k − τ1),
dpik = g˙2(τ1, τ2)(1 − pi)(τ2k − τ2) − g˙1(τ1, τ2)pi(τ1k − τ1),
Σww =

w1(1 − w1) · · · −w1wK
· · · · · · · · ·
−wKw1 · · · wK(1 − wK)

and
Σpipi = pi(1 − pi)

(1 − w1)/w1 · · · −1
· · · · · · · · ·
−1 · · · (1 − wK)/wK
 .
It follows from Steck (1957), as n→ ∞,Un|Vn = v converges weakly to a limiting
distribution in the sense that for any sequence {vn} such that vn ∈ An, the range of
Vn, and limn→∞ vn = v,
sup
u
|Fvnn (u) − Fv(u)| = o(1),
where Fvnn (u) is the cumulative distribution function of Un conditional on Vn = vn
and Fv(u) is the cumulative distribution function of U0 conditional on V0 = v.
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Furthermore, since |ξθ|+ |ξpi| = o(n−1/2) almost surely, for any δn = (δ′nw, δ′npi)′ → δ,
P
{
n1/2(θˆ − θ) ≤ u | n1/2(wˆk − wk) = δnw, n1/2(pˆik − p¯i) = δnpi
}
=P
{
Un ≤ u − n1/2ξθ | Vn = (δ′nw, δ′npi − n1/2ξ′pi)′
}
=F v˜nn (u − n1/2ξθ)
=Fδ(u − n1/2ξθ) + o(1)
=Fδ(u) + o(1),
where v˜n = (δ′nw, δ
′
npi−n1/2ξ′pi)′ → δ. Therefore, the conditional distribution n1/2(θˆ−
θ) | n1/2(wˆk − wk), n1/2(pˆik − p¯i) converges to the normal distribution with a mean
bθ and variance σ2ad j. Next, we will derive the explicit expression for mean bθ and
variance σ2ad j. We first note that the variance-covariance matrices Σpipi and Σww are
singular, the conditional distribution U0|V0 is the same as that only conditioning
on the components corresponding to (w1, · · · ,wK−1, pi1, · · · , piK−1)′. Let D˜θpi D˜θw,
Σ˜ww and Σ˜pipi be the associated covariance vectors and variance matrices.
bθ =n1/2(wˆ1 − w1, · · · , wˆK−1 − wK−1)Σ˜−1θwD˜θpi + n1/2(pˆi1 − p¯i, · · · , pˆiK−1 − p¯i)Σ˜−1pipi D˜θpi
=n1/2

wˆ1 − w1
...
wˆK−1 − wK−1

′ 
g˙2(τ1, τ2)

τ21 − τ2K
...
τ2(K−1) − τ2K
 + g˙1(τ1, τ2)

τ11 − τ1K
...
τ1(K−1) − τ1K


+ n1/2

pˆi1 − p¯i
...
pˆiK−1 − p¯i

′ 
g˙2(τ1, τ2)
pi

w1(τ21 − τ2K)
...
wK−1(τ2(K−1) − τ2K)
 −
g˙1(τ1, τ2)
1 − pi

w1(τ11 − τ1K)
...
wK−1(τ1(K−1) − τ1K)


=n1/2
g˙2(τ1, τ2) K∑
k=1
{
wˆk − wk + wˆk(pˆik − p¯i)
p¯i
}
τ2k + g˙1(τ1, τ2)
K∑
k=1
{
wˆk − wk − wˆk(pˆik − p¯i)1 − p¯i
}
τ1k
 + op(1)
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which is asymptotically equivalent to n1/2(θˆpiw− θˆ). It is clear that the bias of θˆ can
then be consistently estimated by bˆpiw.
For the conditional variance, we first have
σ2piw = σ
2
θ − D˜′θwΣ˜−1wwD˜θw − D˜′θpiΣ˜−1pipi D˜θpi.
Since
D˜′θwΣ˜
−1
wwD˜θw =D˜
′
θw
g˙2(τ1, τ2)

τ21 − τ2K
...
τ2(K−1) − τ2K
 + g˙1(τ1, τ2)

τ11 − τ1K
...
τ1(K−1) − τ1K


=
K∑
k=1
wk {g˙2(τ1, τ2)(τ2k − τ2) + g˙1(τ1, τ2)(τ1k − τ1)}2 ,
D˜′θwΣ˜
−1
wwD˜θw =D˜
′
θw

g˙2(τ1, τ2)
pi

w1(τ21 − τ2K)
...
wK−1(τ2(K−1) − τ2K)
 −
g˙1(τ1, τ2)
1 − pi

w1(τ11 − τ1K)
...
wK−1(τ1(K−1) − τ1K)


=
g˙2(τ1, τ2)2
pi
K∑
k=1
wk(τ22k − τ22) +
g˙1(τ1, τ2)2
1 − pi
K∑
k=1
wk(τ21k − τ21)
−
K∑
k=1
wk {g˙2(τ1, τ2)(τ2k − τ2) + g˙1(τ1, τ2)(τ1k − τ1)}2 ,
and σ2Y j =
∑K
k=1 wk(σ
2
Y jk + τ
2
jk) − τ2j , we have
σ2ad j =
g˙2(τ1, τ2)2
pi
K∑
k=1
wkσ2Y2k +
g˙1(τ1, τ2)2
1 − pi
K∑
k=1
wkσ2Y1k,
where σ2Y jk = var(Yi|Ri = j, Xi = k). Furthermore, the conditional variance of θˆ− θ
can be consistently estimated by σˆ2piw =
∑K
k=1
{
g˙2(τ
†
1, τ
†
2)
2wˆ2kσˆ
2
2k + g˙1(τ
†
1, τ
†
2)
2wˆ2kσˆ
2
1k
}
.
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In the aforementioned derivation, we used the fact that
Σ˜ww

τ j1 − τ jK
...
τ j(K−1) − τ jK
 =

w1(τ j1 − τ j)
...
wK−1(τ j(K−1) − τ j)

and
Σ˜pipi

w1(τ j1 − τ jK)
...
wK−1(τ j(K−1) − τ jK)
 = pi(1 − pi)

τ j1 − τ j
...
τ j(K−1) − τ j
 , j = 1, 2.
Appendix B: Incompatibility of PH assumption in the entire study
and within stratum
Assume that the PH assumption holds within each of the K strata. Let S jk(t)
denote the survival function in the kth stratum of arm j, j = 1, 2. Then we have
S 2k(t) = S 1k(t)r0
for k = 1, · · · ,K and a common HR r0. Furthermore, the marginal survival func-
tion for the entire study population is
S j(t) =
K∑
k=1
wkS jk(t),
for arm j, where w1 + · · ·+wK = 1,wk ∈ (0, 1), k = 1, · · · ,K. If the PH assumption
holds for the marginal survival function, then S 2(t) = S 1(t)r for a constant r, i.e., K∑
k=1
wkS 1k(t)

r
=
K∑
k=1
wkS 1k(t)r0 .
Taking derivative with respect to t for both sides at t = 0, we obtain that
r =
r0
∑K
k=1 wkS 1k(0)
r0−1 f1k(0)∑K
k=1 wk f1k(0)
(∑K
k=1 wkS 1k(0)
)r−1 = r0.
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Without loss of generality, we assume that r0 ≥ 1, otherwise we always can switch
two groups of interest to ensure that the HR is greater than or equal to 1. Under
this assumption
S 2(t) =
K∑
k=1
wkS 1k(t)r0 ≥
 K∑
k=1
wkS 1k(t)
r0 = S 1(t)r0 ,
for 0 < S 1k(t) < 1 due to the convexity of the function xr0 . The equality holds only
when S 11(t) = · · · = S 1K(t) or r0 = 1. Thus the PH model with a HR of r0 is not
true for the entire study population unless S 11(t) = · · · = S 1K(t), i.e., the survival
distributions are the same across strata or r0 = 1, i.e., there is no difference in
survivorship in any stratum.
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Table 1: Stratified event rate of death or hospitalization up to 18 months in Aus-
tralia region of VALIANT Study
stratification factors Australia Data pˆik OR
(# of events / # of patients)
BMI History of Diabetes Monotherapy Combo therapy
< 25 No 43/60 8/13 0.82 0.63
< 25 Yes 9/10 6/8 0.56 0.33
≥ 25 No 65/108 44/54 0.67 2.91
≥ 25 Yes 18/24 22/25 0.49 2.44
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Figure 1: The survival curves for entire VALIANT study by arms: monotherapy
and combo therapy arms.
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Figure 2: The survival curves for Australian patients in VALIANT study by arms:
monotherapy and combo therapy arms.
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